Як цитувати

Parchami , G. S., & Hameed , M. (2021). NOVEL AGENTS FOR THE TREATMENT OF HEART FAILURE. ГРААЛЬ НАУКИ, (5), 364-365.


Berliner, D., & Bauersachs, J. (2019). New drugs: big changes in conservative heart failure therapy?. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 55(Suppl 1), i3–i10.

Li, H., Duan, Y., Chen, B., Zhao, Y., Su, W., Wang, S., … Lu, L. (2020). New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): A Bayesian network meta-analysis. Medicine, 99(5), e18341.

Machaj, F., Dembowska, E., Rosik, J., Szostak, B., Mazurek-Mochol, M., & Pawlik, A. (2019). New therapies for the treatment of heart failure: a summary of recent accomplishments. Therapeutics and clinical risk management, 15, 147–155.

4-Metra, M., Teerlink, J. R., Cotter, G., Davison, B. A., Felker, G. M., Filippatos, G., …Crespo-Leiro, M. G. RELAX-AHF-2 Committees Investigators (2019). Effects of Serelaxin in Patients with Acute Heart Failure. The New England journal of medicine, 381(8), 716–726.

Papp, Z., Agostoni, P., Alvarez, J., Bettex, D., Bouchez, S., Brito, D., … Pollesello, P. (2020). Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. Cardiac failure review, 6, e19.

Savarese, G., & Lund, L. H. (2017). Global Public Health Burden of Heart Failure. Cardiac failure review, 3(1), 7–11.

Creative Commons License

Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.

| Переглядів: 13 | Завантажень: 19 |